Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing and currently employs 1,306 full-time employees. The company went IPO on 2022-09-01. The firm utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The firm is also engaged in the provision of gene-editing services. The firm operates its businesses in the domestic market and overseas markets.
02315.HK stock price ended at $40.88 on 月曜日, after dropping 5.55%
On the latest trading day Jan 19, 2026, the stock price of 02315.HK fell by 5.55%, dropping from $43.28 to $40.88. During the session, the stock saw a volatility of 7.55%, with prices oscillating between a daily low of $40.24 and a high of $43.28. On the latest trading day, the trading volume for 02315.HK rose by 202.0K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 859.0K shares were traded, with a market value of approximately $4.3B.